Alkermes Plc  

(Public, NASDAQ:ALKS)   Watch this stock  
Find more results for alks
39.75
-1.54 (-3.73%)
Apr 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 39.40 - 41.40
52 week 27.14 - 80.71
Open 40.97
Vol / Avg. 1.09M/1.52M
Mkt cap 5.78B
P/E     -
Div/yield     -
EPS -1.83
Shares 151.08M
Beta 1.81
Inst. own 96%
Jul 28, 2016
Q2 2016 Alkermes Plc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
May 26, 2016
Alkermes Plc Annual Shareholders Meeting (Estimated) - 7:00AM EDT - Add to calendar
May 25, 2016
Alkermes Plc Annual Shareholders Meeting - 7:00AM EDT - Add to calendar
Apr 28, 2016
Q1 2016 Alkermes Plc Earnings Release
Apr 28, 2016
Q1 2016 Alkermes Plc Earnings Call - Webcast
Mar 16, 2016
Alkermes Plc at Barclays Global Healthcare Conference
Mar 8, 2016
Alkermes Plc at Cowen Health Care Conference
Mar 1, 2016
Alkermes Plc at Credit Suisse One-on-One Healthcare Conference
Feb 25, 2016
Q4 2015 Alkermes Plc Earnings Release
Feb 25, 2016
Q4 2015 Alkermes Plc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -49.39% -36.15%
Operating margin -49.04% -35.70%
EBITD margin - -22.08%
Return on average assets -17.01% -12.04%
Return on average equity -24.08% -16.76%
Employees 1,500 -
CDP Score - -

Address

1 Burlington Road, Connaught House
DUBLIN, 00000
Ireland
+353-1-7728000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of approximately 20 products and a clinical pipeline of product candidates that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis. Its products include ARISTADA, VIVITROL, RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION & INVEGA TRINZA, AMPYRA/FAMPYRA, BYDUREON, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, Aripiprazole Lauroxil Two-Month Dose, ALKS 7119 and RDB 1450. Its product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release technology.

Officers and directors

Richard F. Pops Chairman, President, and CEO
James M. (Jim) Frates SVP, CFO, and Treasurer
Gordon G. Pugh SVP, COO, and Chief Risk Officer
Richard F. Pops Chairman of the Board, Chief Executive Officer
Age: 52
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Shane M. Cooke President
Age: 52
Bio & Compensation  - Reuters
James M. Frates Chief Financial Officer, Senior Vice President
Age: 47
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Gordon G. Pugh Chief Operating Officer, Senior Vice President, Chief Risk Officer
Age: 57
Bio & Compensation  - Reuters
Elliot W. Ehrich M.D. Executive Vice President, Research and Development and Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
Kathryn L. Biberstein Senior Vice President, Chief Legal Officer and Chief Compliance Office, Secretary
Age: 56
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Rebecca J. Peterson Senior Vice President - Corporate Communications
Age: 39
Bio & Compensation  - Reuters